Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)
Novartis' Entresto infringes on university patents, lawsuit claims
More than a year and a half after securing FDA approval for a blockbuster heart drug, Novartis is now going to court over it. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
